MBX (MBX Biosciences) Common Stock : $0.01 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Common Stock?

MBX Biosciences's quarterly common stock increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.01 Mil) but then stayed the same from Sep. 2024 ($0.01 Mil) to Dec. 2024 ($0.01 Mil).

MBX Biosciences's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.01 Mil).

MBX Biosciences Common Stock Historical Data

The historical data trend for MBX Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Common Stock Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Common Stock

0.01

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial			-	-	-	0.01	0.01

MBX Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.